文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19患者呼吸机相关性肺炎的发病率、微生物学与免疫学特征:CoV-AP研究

Incidence, microbiological and immunological characteristics of ventilator-associated pneumonia assessed by bronchoalveolar lavage and endotracheal aspirate in a prospective cohort of COVID-19 patients: CoV-AP study.
PubMed 文献 · Crit Care · 2023-09-26
一句话结论在COVID-19机械通气患者中,ETA与BAL采样导致VAP发病率差异显著(33.1 vs 20.1/1000通气日),BALFAPPP敏感性高但特异性有限,BAL IL-1β在VAP组显著升高。

这项前瞻性单中心队列研究纳入79例COVID-19机械通气患者,同时采集ETA和BAL进行常规与快速微生物学检测及免疫标志物分析。结果显示,以ETA和BAL为诊断依据的VAP发病率分别为33.1(95%CI 22.1-44.0)和20.1(95%CI 12.5-27.7)/1000通气日;以BAL为参考,ETA敏感性88.9%、特异性50.0%,BALFAPPP敏感性95.0%、特异性69%。BAL IL-1β在VAP组显著高于无VAP组(P=0.03)。作者认为采样方式差异可导致VAP发病率与微生物学结果显著变异,BAL IL-1β可能有助于鉴别微生物学确诊的VAP。

要点

  • 以BAL为参考标准,ETA诊断VAP的敏感性为88.9%(95%CI 70.8-97.7),特异性仅50.0%(95%CI 28.2-71.8),Cohen's Kappa 0.40(95%CI 0.16-0.65)。
  • BALFAPPP诊断VAP的敏感性为95.0%(95%CI 75.1-99.9),特异性为69%(95%CI 49.2-84.7),Cohen's Kappa 0.60(95%CI 0.39-0.81)。
  • ETA与BAL的一致性为35/49(71.4%),BALFAPPP与BAL的一致性为39/49(79.6%)。
  • BAL IL-1β在VAP组为135(IQR 11-450)pg/ml,无VAP组为10(IQR 2.9-105)pg/ml,组间差异P=0.03。
  • 以ETA和BAL为诊断依据的VAP发病率分别为33.1(95%CI 22.1-44.0)和20.1(95%CI 12.5-27.7)/1000通气日。

适用人群与场景

  • COVID-19机械通气患者,来自意大利米兰Policlinico医院,2021年1月至2022年5月期间收治。
  • 纳入79例患者,ICU入住前抗生素暴露51/79(64.6%),激素治疗60/79(65.9%)。
  • VAP怀疑时机械通气中位时间为6(5-9)天。

诊断标准与关键阈值

  • 疑似VAP(sVAP)的微生物学确认基于同时采集的ETA和BAL。

研究设计与关键结果

  • 前瞻性单中心队列研究,纳入79例COVID-19机械通气患者。
  • 主要结果:以ETA和BAL为诊断依据的VAP发病率分别为33.1(95%CI 22.1-44.0)和20.1(95%CI 12.5-27.7)/1000通气日。
  • ETA与BAL一致性35/49(71.4%);BALFAPPP与BAL一致性39/49(79.6%)。
  • 以BAL为参考标准,ETA敏感性88.9%(95%CI 70.8-97.7),特异性50.0%(95%CI 28.2-71.8),Cohen's Kappa 0.40(95%CI 0.16-0.65)。
  • BALFAPPP敏感性95.0%(95%CI 75.1-99.9),特异性69%(95%CI 49.2-84.7),Cohen's Kappa 0.60(95%CI 0.39-0.81)。
  • BAL IL-1β在VAP组为135(IQR 11-450)pg/ml,无VAP组为10(IQR 2.9-105)pg/ml,P=0.03。

证据类型、等级与局限

  • 证据类型:前瞻性单中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在COVID-19机械通气患者中,不同呼吸道采样方式(ETA vs BAL)可导致VAP发病率与微生物学结果显著变异,比较不同队列结果时需考虑采样差异。
  • 以BAL为参考标准时,ETA阳性而BAL阴性的样本超过20%,是两者一致性的主要限制因素。
  • BALFAPPP在仅评估面板内靶标时显示高敏感性但特异性有限。
  • 作者认为BAL IL-1β在鉴别微生物学确诊的VAP方面显示出潜力。

指南或共识出处

  • 临床试验注册号NCT04766983,注册于2021年2月23日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: No univocal recommendation exists for microbiological diagnosis of ventilator-associated pneumonia (VAP). Sampling of either proximal or distal respiratory tract likely impacts on the broad range of VAP incidence between cohorts. Immune biomarkers to rule-in/rule-out VAP diagnosis, although promising, have not yet been validated. COVID-19-induced ARDS made VAP recognition even more challenging, often leading to overdiagnosis and overtreatment. We evaluated the impact of different respiratory samples and laboratory techniques on VAP incidence and microbiological findings in COVID-19 patients.

METHODS: Prospective single-centre cohort study conducted among COVID-19 mechanically ventilated patients in Policlinico Hospital (Milan, Italy) from January 2021 to May 2022. Microbiological confirmation of suspected VAP (sVAP) was based on concomitant endotracheal aspirates (ETA) and bronchoalveolar lavage (BAL). Conventional and fast microbiology (FILMARRAY® Pneumonia Panel plus, BALFAPPP) as well as immunological markers (immune cells and inflammatory cytokines) was analysed.

RESULTS: Seventy-nine patients were included. Exposure to antibiotics and steroid therapy before ICU admission occurred in 51/79 (64.6%) and 60/79 (65.9%) patients, respectively. Median duration of MV at VAP suspicion was 6 (5-9) days. Incidence rate of microbiologically confirmed VAP was 33.1 (95% CI 22.1-44.0) and 20.1 (95% CI 12.5-27.7) according to ETA and BAL, respectively. Concordance between ETA and BAL was observed in 35/49 (71.4%) cases, concordance between BALFAPPP and BAL in 39/49 (79.6%) cases. With BAL as reference standard, ETA showed 88.9% (95% CI 70.8-97.7) sensitivity and 50.0% (95% CI 28.2-71.8) specificity (Cohen's Kappa 0.40, 95% CI 0.16-0.65). BALFAPPP showed 95.0% (95% CI 75.1-99.9) sensitivity and 69% (95% CI 49.2-84.7) specificity (Cohen's Kappa 0.60, 95% CI 0.39-0.81). BAL IL-1β differed significantly between VAP (135 (IQR 11-450) pg/ml) and no-VAP (10 (IQR 2.9-105) pg/ml) patients (P = 0.03).

CONCLUSIONS: In COVID-19 ICU patients, differences in microbial sampling at VAP suspicion could lead to high variability in VAP incidence and microbiological findings. Concordance between ETA and BAL was mainly limited by over 20% of ETA positive and BAL negative samples, while BALFAPPP showed high sensitivity but limited specificity when evaluating in-panel targets only. These factors should be considered when comparing results of cohorts with different sampling. BAL IL-1β showed potential in discriminating microbiologically confirmed VAP.

CLINICAL TRIAL REGISTRATION: NCT04766983, registered on February 23, 2021.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Mangioni D, Panigada M, Palomba E, et al. Incidence, microbiological and immunological characteristics of ventilator-associated pneumonia assessed by bronchoalveolar lavage and endotracheal aspirate in a prospective cohort of COVID-19 patients: CoV-AP study. Crit Care. 2023. PMID: 37749631. doi:10.1186/s13054-023-04658-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。